Topic: mesothelioma

Owkin's mesothelioma AI discovers new tissue biomarkers

by Conor Hale

Monday, October 7, 2019

By scanning thousands of tissue samples, a deep learning program developed by Owkin was able to help identify new types of patients with mesothelioma.

Novocure nets approval for electric-field mesothelioma therapy

by Conor Hale

Friday, May 24, 2019

Novocure’s tumor-treating electric field system scored an FDA nod in mesothelioma, making it the first new treatment in more than 15 years.

Novocure promotes Pritesh Shah to chief commercial officer

by Conor Hale

Thursday, July 5, 2018

Novocure named Pritesh Shah chief commercial officer, to lead the tumor-treating device manufacturer’s international business units.

Novocure plans FDA filing as anti-cancer device clears phase 2

by Nick Paul Taylor

Wednesday, April 18, 2018

Novocure wants to bring the electric field device to market in mesothelioma via the rarely used humanitarian device exemption.

CRUK, Biotecnol team up for T-cell engager trial

by Nick Paul Taylor

Wednesday, August 9, 2017

The deal sees CRUK take a stake in the biotech in return for help testing a 5T4-CD3 bispecific antibody in patients with solid tumors.

Sellas snags Nasdaq listing in reverse merger with Galena

by Nick Paul Taylor

Tuesday, August 8, 2017

The deal gives Sellas a route to public investors as it seeks to guide its WT1-targeting drug through phase 3 trials in AML and mesothelioma.

Bayer ADC fails pivotal mesothelioma trial

by Nick Paul Taylor

Monday, July 24, 2017

The drug failed to improve progression-free survival in mesothelioma, causing the stocks of Bayer’s collaborators ImmunoGen and MorphoSys to slip.

Cell Medica buys clinical-phase WT1-TCR cell therapy

by Nick Paul Taylor

Tuesday, June 20, 2017

Cell Medica has bought Catapult Therapy TCR for its clinical-phase WT1 T-cell receptor cell therapy.

6. AstraZeneca

by Ben Adams

AstraZeneca had a pretty rough few years of R&D setbacks and failures up until 2012, when its former chief, David Brennan, was all but pushed out as a result. But things seem to have steadied somewhat since Pascal Soriot took the helm.

Advaxis pens backloaded $358M cancer delivery tech deal

by Nick Paul Taylor

Monday, February 27, 2017

Advaxis has licensed its antigen delivery technology for use in Sellas’ cancer immunotherapy.

GET THE NEWSLETTER

Subscribe to FierceBiotech to get industry news and updates delivered to your inbox.